William Blair initiates Neuronetics stock at Outperform on strategy shift
William Blair initiated coverage on Neuronetics Inc. (NASDAQ:STIM) with an Outperform rating, citing positive results from new strategies. The company's NeuroStar system is now offered through flexible purchasing models, and Greenbrook clinics are focusing on efficiency. Sales grew 11% YoY in Q2 and Q3 2026, with adjusted EBITDA improving to $2 million from negative $10 million YoY.
How this was made
The 30-second read
Why it matters
Analyst initiation may provide a modest catalyst, but the core news is a recap of previously released earnings and operational metrics.
Market read
Limited impact; the primary news is an analyst upgrade on a stock that has already reported its quarterly results.
What to watch
Cash burn remains high and earnings guidance is still weak, which could limit upside.
Background
The article reports William Blair's new coverage of Neuronetics (STIM) with an Outperform rating, referencing strategy changes and recent earnings that were already public.
Ticker impact
William Blair initiates coverage with an Outperform rating, citing recent strategy shift and early results.
potential upward pressure as investors price in the positive strategy shift
The upgrade is based on early operational improvements, but the company remains unprofitable and the news recaps already‑released earnings.
Market effects
Highlights potential for other neuro‑stimulation firms to benefit from flexible purchasing models.
Limited to U.S. mental‑health device market.
Low
Counterpoint
The stock's recent 36% decline suggests lingering concerns about profitability that may outweigh the analyst's optimism.
Key entities
- companyNeuronetics Inc.
Neuro‑stimulation device maker (NASDAQ:STIM).
- analyst_firmWilliam Blair
Investment bank that initiated coverage.

